subscribeSubscribe
Novartis Shows Data of Leqvio Significantly Reduces LDL-C in ASCVD Patients

Novartis Shows Data of Leqvio Significantly Reduces LDL-C in ASCVD Patients
GLOBENEWSWIRE
06 Apr 2024
Share Share
?Novartis presents new long-term Leqvio® (inclisiran) data efficacy and safety

?Novartis presents new long-term Leqvio® (inclisiran) data efficacy and safety
PR NEWSWIRE
28 Aug 2023
Share Share
siRNA therapy shows long-term potential in lowering LDL-C

siRNA therapy shows long-term potential in lowering LDL-C
Catherine Eckford EUROPEAN PHARMACEUTICAL REVIEW
28 Aug 2023
Share Share
FDA Approves Expanded Indication for Leqvio

FDA Approves Expanded Indication for Leqvio
PR NEWSWIRE
11 Jul 2023
Share Share
Novartis scraps UK heart attack prevention trial

Novartis scraps UK heart attack prevention trial
REUTERS
23 Mar 2023
Share Share
New long-term Leqvio® data from Novartis show sustained efficacy and safety

New long-term Leqvio® data from Novartis show sustained efficacy and safety
GLOBENEWSWIRE
07 Nov 2022
Share Share
Soleo Selected as Limited Drug Distribution Partner for Administration of LEQVIO

Soleo Selected as Limited Drug Distribution Partner for Administration of LEQVIO
BUSINESSWIRE
01 Aug 2022
Share Share
Novartis` Leqvio poised to rake in $2.5B, overtake competition

Novartis` Leqvio poised to rake in $2.5B, overtake competition
Kevin Dunleavy FIERCEPHARMA
23 Feb 2022
Share Share
Novartis wins FDA approval for new heart drug, but faces uphill sales battle

Novartis wins FDA approval for new heart drug, but faces uphill sales battle
J. Gardner BIOPHARMADIVE
23 Dec 2021
Share Share
FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA

FDA approves Novartis Leqvio® (inclisiran), first-in-class siRNA
GLOBENEWSWIRE
22 Dec 2021
Share Share